Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2018-09-01
Metadata
Show full item recordAbstract
Budesonide is a hydrophobic glucocorticoid with high anti-inflammatory activity for the treatment of asthma, inflammatory bowel disease and rheumatoid arthritis. A micellar drug-delivery system based on lipid-DNA may provide a strategy to maximize its drug efficacy and reduce adverse effects. In this work, we report the use of lipid-DNAA (UU11mer), featuring two hydrophobic alkyl chains and forming micelles at a comparatively low critical micelle concentration, to render budesonide water-soluble with a high loading capacity (LC). The inhibition of interleukin-8 (IL-8) release shows that the new delivery system retains the inhibitory activity in cell-based assays. In conclusion, this research provides a novel approach to formulate and administer budesonide in a non-invasive manner, which dramatically improves its water-solubility while retaining its bioavailability.Affiliation
HIPS, Helmholtz-Institut für pharmazeutische Forschung Saarland, Universitätscampus 8.1, 66123 Saarbrücken, Germany.PubMed ID
29908939Type
ArticleISSN
1873-3441ae974a485f413a2113503eed53cd6c53
10.1016/j.ejpb.2018.06.012
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States
Related articles
- Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.
- Authors: Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YT
- Issue date: 2011
- Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
- Authors: Ahmadi F, Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Mahzouni P, Dorkoosh F
- Issue date: 2011 Feb
- Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
- Authors: Leonard F, Srinivasan S, Liu X, Collnot EM, Ferrari M, Lehr CM, Godin B
- Issue date: 2020 Jun
- Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
- Authors: Sinhmar GK, Shah NN, Chokshi NV, Khatri HN, Patel MM
- Issue date: 2018 Jul
- Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
- Authors: Beloqui A, Coco R, Alhouayek M, Solinís MÁ, Rodríguez-Gascón A, Muccioli GG, Préat V
- Issue date: 2013 Oct 1